Dynal Biotech of Norway is now a wholly owned subsidiary of Invitrogen Corp., the Carlsbad company announced Friday.
Invitrogen paid $391 million in cash for Dynal, a maker of diagnostic tools for biotechnology research. The technology complements Invitrogen’s technology portfolio.
Invitrogen announced its plans to acquire Dynal in February. At that time, the company said it would pay $386 million.
The seller was Nordic Capital and a co-investor.
Invitrogen trades on the Nasdaq as IVGN.